LNTH — Lantheus Holdings, Inc.
—
Nasdaq ·
Health Care ·
Life Sciences Tools & Services ·
CIK 1521036 ·
Last close
$101.80
Market Cap
$6.66B
52W High
$111.86
52W Low
$51.84
ADV30
1,022,256
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | — | — | — | — | — | — | — |
| Jun 2026 | 388,180,000 | 241,855,000 | 100,215,000 | 75,029,000 | 2,414,662,000 | 593,298,000 | 1,102,884,000 |
| Mar 2026 | 377,333,000 | 230,922,000 | 81,326,000 | 118,417,000 | 2,346,587,000 | 498,582,000 | 1,134,299,000 |
| Dec 2025 | 406,786,000 | 240,875,000 | 77,184,000 | 54,088,000 | 2,227,399,000 | 359,121,000 | 1,137,602,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$412,802,000
Investing CF
$-307,015,000
Financing CF
$-207,070,000
CapEx
$-24,971,000
Dividends Paid
—
Buybacks
$-200,017,000
EPS Diluted TTM
$4.06
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$872,950,000
Inventory
$57,551,000
Receivables
$354,056,000
ST Investments
—
EBIT TTM
$382,783,000
Pretax Income TTM
$362,976,000
Interest Exp TTM
$19,807,000
Analysts
8
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,562,211,968
EBITDA
$354,720,000
Free Cash Flow
$403,712,384
Enterprise Value
$6,520,709,120
Total Cash
$683,609,984
Total Debt
$624,283,008
Shares Out
65,401,413
Trailing EPS
$4.02
Book Value
$20.74
ROE
21.8%
ROA
7.0%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 1,541,609,000 | 315,559,000 | 233,559,000 | 2,227,399,000 | 1,137,602,000 | 1,089,797,000 | 390,141,000 |
| Dec 2024 | 1,533,910,000 | 448,564,000 | 312,442,000 | 1,980,340,000 | 892,329,000 | 1,088,011,000 | 544,750,000 |
| Dec 2023 | 1,296,429,000 | 364,642,000 | 326,661,000 | 1,651,149,000 | 835,257,000 | 815,892,000 | 305,260,000 |
| Dec 2022 | 935,061,000 | 36,195,000 | 28,067,000 | 1,321,258,000 | 874,111,000 | 447,147,000 | 281,781,000 |
TTM Snapshot
Revenues TTM
$1,556,313,000
NetIncome TTM
$275,305,000
OpCashFlow TTM
—
Assets (Latest)
$2,414,662,000
Forward EPS
$6.48
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ICLR | ICON PLC | $15.05B | $195.02 | — |
| CRL | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | $15.92B | $332.16 | — |
| MEDP | Medpace Holdings, Inc. | $18.27B | $653.09 | — |
| NEOG | NEOGEN CORP | $2.38B | $10.90 | — |
| CLDX | Celldex Therapeutics, Inc. | $2.20B | $28.04 | — |
News headlines (Yahoo Finance, 1h cache)
Lantheus Presents Data from Two Pivotal Phase 3 Studies of TAUKLARIFY (Florquinitau F 18 Injection) PET Imaging in Early Alzheimer’s Disease
2026-11-16 14:00 · Yahoo
PharmaLogic to Acquire Lantheus' CDMO Business and Springfield, New Jersey Manufacturing Facility
2026-11-09 21:05 · Yahoo
Lantheus Holdings: Q3 Earnings Snapshot
2026-11-05 12:22 · Yahoo
Lantheus Welcomes CMS CY27 Final Rule Advancing Access to Diagnostic Radiopharmaceuticals
2026-11-05 12:15 · Yahoo
Lantheus Announces Presentation of Data at the 2026 Clinical Trials on Alzheimer’s Disease Annual Meeting
2026-11-02 13:30 · Yahoo
Lantheus Announces CMS Grants Transitional Pass-Through Status for PYLARIFY® TruVu (piflufolastat F 18)
2026-09-30 12:30 · Yahoo
Lantheus Announces First Patient Dosed in SPARROW Phase 2/3 Registrational Trial in Prostate Cancer
2026-09-28 12:00 · Yahoo
Lantheus Holdings (LNTH) Could Be 7% Undervalued On BRAVNETSA Approval
2026-09-26 18:10 · Yahoo
Lantheus Holdings (LNTH) Stock May Be 14% Undervalued On FDA Approval
2026-09-26 02:08 · Yahoo
3 Reasons LNTH is Risky and 1 Stock to Buy Instead
2026-09-23 13:57 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.